ArticleGynecology and pelvic medicine2025
Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004.
Yusuke Taira et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.